UA112154C2 - Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів - Google Patents

Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів Download PDF

Info

Publication number
UA112154C2
UA112154C2 UAA201204308A UAA201204308A UA112154C2 UA 112154 C2 UA112154 C2 UA 112154C2 UA A201204308 A UAA201204308 A UA A201204308A UA A201204308 A UAA201204308 A UA A201204308A UA 112154 C2 UA112154 C2 UA 112154C2
Authority
UA
Ukraine
Prior art keywords
fibrosis
sho
group
map
shi
Prior art date
Application number
UAA201204308A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кристофер ВЕСТОН
Лі Чарльз Кларидж
Ли Чарльз КЛАРИДЖ
Девід Адамс
Дэвид АДАМС
Девід Сміт
Дэвид Смит
Ніна Вестерлунд (померла)
Нина Вестерлунд (умершая)
Марджо Піхлавісто
Марджо Пихлависто
Туа Остерман (померла)
Туа Остерман (умершая)
Original Assignee
Біоті Терапіс Корп.
Биоти Тэрапис Корп.
Дзе Юніверсіті Оф Бірмінгем
Дзе Юниверсити Оф Бирмингем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Біоті Терапіс Корп., Биоти Тэрапис Корп., Дзе Юніверсіті Оф Бірмінгем, Дзе Юниверсити Оф Бирмингем filed Critical Біоті Терапіс Корп.
Publication of UA112154C2 publication Critical patent/UA112154C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
UAA201204308A 2009-09-08 2010-07-09 Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів UA112154C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24040209P 2009-09-08 2009-09-08
US32303210P 2010-04-12 2010-04-12
PCT/FI2010/050689 WO2011029996A1 (en) 2009-09-08 2010-09-07 Use of vap-1 inhibitors for treating fibrotic conditions

Publications (1)

Publication Number Publication Date
UA112154C2 true UA112154C2 (uk) 2016-08-10

Family

ID=43732037

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201204308A UA112154C2 (uk) 2009-09-08 2010-07-09 Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів

Country Status (27)

Country Link
US (2) US9795671B2 (enExample)
EP (1) EP2475387B1 (enExample)
JP (3) JP6009355B2 (enExample)
KR (2) KR20180026808A (enExample)
CN (2) CN107661500A (enExample)
AU (1) AU2010294123B2 (enExample)
CA (1) CA2773218C (enExample)
CY (1) CY1119867T1 (enExample)
DK (1) DK2475387T3 (enExample)
ES (1) ES2657943T3 (enExample)
HR (1) HRP20180131T1 (enExample)
HU (1) HUE035890T2 (enExample)
IL (1) IL218535A (enExample)
LT (1) LT2475387T (enExample)
ME (1) ME02999B (enExample)
NO (1) NO2475387T3 (enExample)
NZ (3) NZ598920A (enExample)
PL (1) PL2475387T3 (enExample)
PT (1) PT2475387T (enExample)
RS (1) RS56809B1 (enExample)
RU (2) RU2667963C1 (enExample)
SG (1) SG179012A1 (enExample)
SI (1) SI2475387T1 (enExample)
SM (1) SMT201800043T1 (enExample)
UA (1) UA112154C2 (enExample)
WO (1) WO2011029996A1 (enExample)
ZA (1) ZA201202515B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112154C2 (uk) * 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
JP5953035B2 (ja) * 2011-11-28 2016-07-13 学校法人慶應義塾 病理診断支援装置、病理診断支援方法、及び病理診断支援プログラム
CA3086105A1 (en) 2012-05-02 2013-11-07 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
WO2014024820A1 (ja) * 2012-08-06 2014-02-13 塩野義製薬株式会社 新規慢性腎臓病治療用医薬組成物及び新規慢性腎臓病治療薬のスクリーニング方法
KR102205845B1 (ko) 2013-10-28 2021-01-22 삼성전자주식회사 입자에 기반한 모델링 방법 및 장치
WO2015189534A1 (en) * 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
JP2018080114A (ja) * 2015-05-29 2018-05-24 株式会社アールテック・ウエノ 抗ヒトｖａｐ−１モノクローナル抗体
WO2019003159A1 (en) * 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
EP4482869A4 (en) * 2022-02-23 2025-12-17 Univ Yale IL-6 inhibitor for the treatment of nephropathia
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997854A (en) * 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5580780A (en) 1992-06-09 1996-12-03 Jalkanen; Sirpa Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies
CA2289903A1 (en) * 1997-05-23 1998-11-26 Oy Biotie Therapies, Ltd. Vascular adhesion protein-1 having amine oxidase activity
AU8216301A (en) 2000-07-05 2002-01-14 Biotie Therapies Corp Inhibitors of copper-containing amine oxidases
WO2002038153A1 (en) 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
EP1353676A4 (en) 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
FI20020807A0 (fi) * 2002-04-29 2002-04-29 Biotie Therapies Oyj Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
US7125901B2 (en) 2003-01-27 2006-10-24 Astellas Pharma Inc. Thiazole derivatives
EP1608365B1 (en) 2003-03-31 2013-10-02 R-Tech Ueno, Ltd. Method for treating vascular hyperpermeable disease
WO2005014530A2 (en) 2003-08-08 2005-02-17 La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases
ATE460935T1 (de) * 2004-01-30 2010-04-15 Faron Pharmaceuticals Oy Besonders nützliche zusammensetzungen für die behandlung oder prävention des metabolischen syndroms
FI20040270A0 (fi) 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
KR20060135781A (ko) 2004-02-25 2006-12-29 라 졸라 파마슈티칼 컴파니 질병의 치료를 위한 아민 및 아미드
ES2331890T3 (es) 2004-03-18 2010-01-19 R-Tech Ueno, Ltd. Composicion acuosa que comprende un derivado de tiazol.
KR20070050932A (ko) * 2004-07-27 2007-05-16 가부시키가이샤 아루떼꾸 우에노 Ｖａｐ―１ 억제 활성을 가지는 티아졸 유도체
US20080269282A1 (en) 2004-08-02 2008-10-30 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
EP1791835A2 (en) 2004-09-09 2007-06-06 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
WO2006094201A2 (en) 2005-03-02 2006-09-08 La Jolla Pharmaceutical Company Semicarbazide-sensitive amide oxidase inhibitors
WO2007005737A2 (en) 2005-07-01 2007-01-11 Case Western Reserve University Amine oxidase inhibitors
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
FI20075278A0 (fi) * 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
WO2009055002A1 (en) 2007-10-24 2009-04-30 La Jolla Pharmaceutical Company Combined inhibitors of cyclooxygenase and semicarbazide-sensitive amine oxidase (ssao) (vascular adhesion protein, vap-1)
CN101917845A (zh) 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
TWI437986B (zh) * 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
HUP0800498A2 (en) 2008-08-06 2010-03-29 Semmelweis Egyetem Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level
US8536210B2 (en) 2008-09-11 2013-09-17 Semmelweis Egyetem Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases
EP2334672B1 (en) * 2008-09-16 2013-11-20 Proximagen Limited 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO
ES2403633T3 (es) 2008-12-04 2013-05-20 Proximagen Limited Compuestos de imidazopiridina
UA112154C2 (uk) * 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів

Also Published As

Publication number Publication date
CA2773218C (en) 2021-05-04
LT2475387T (lt) 2018-03-26
US20180071388A1 (en) 2018-03-15
SG179012A1 (en) 2012-04-27
PT2475387T (pt) 2018-02-06
RU2012113561A (ru) 2013-10-20
KR101837117B1 (ko) 2018-03-09
WO2011029996A1 (en) 2011-03-17
EP2475387A4 (en) 2015-05-13
IL218535A (en) 2016-06-30
JP6009355B2 (ja) 2016-10-19
KR20120088699A (ko) 2012-08-08
RS56809B1 (sr) 2018-04-30
KR20180026808A (ko) 2018-03-13
HUE035890T2 (en) 2018-05-28
CN107661500A (zh) 2018-02-06
SI2475387T1 (en) 2018-04-30
NO2475387T3 (enExample) 2018-03-31
IL218535A0 (en) 2012-07-31
PL2475387T3 (pl) 2018-06-29
NZ598920A (en) 2014-06-27
ES2657943T3 (es) 2018-03-07
SMT201800043T1 (it) 2018-03-08
ZA201202515B (en) 2012-12-27
JP2016147847A (ja) 2016-08-18
DK2475387T3 (en) 2018-02-05
CA2773218A1 (en) 2011-03-17
CN102740886A (zh) 2012-10-17
CY1119867T1 (el) 2018-06-27
HRP20180131T1 (hr) 2018-04-20
US10576148B2 (en) 2020-03-03
RU2580626C2 (ru) 2016-04-10
AU2010294123A1 (en) 2012-04-12
NZ706740A (en) 2016-06-24
ME02999B (me) 2018-10-20
EP2475387A1 (en) 2012-07-18
JP2018104445A (ja) 2018-07-05
JP6290940B2 (ja) 2018-03-07
RU2667963C1 (ru) 2018-09-25
JP2013503915A (ja) 2013-02-04
AU2010294123B2 (en) 2013-11-21
US20130195883A1 (en) 2013-08-01
NZ616432A (en) 2015-04-24
US9795671B2 (en) 2017-10-24
EP2475387B1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
UA112154C2 (uk) Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
Mebratu et al. The aged extracellular matrix and the profibrotic role of senescence-associated secretory phenotype
JP5299900B2 (ja) 糖尿病関連肝臓由来分泌タンパク質の２型糖尿病または血管障害の診断または治療への利用
US11116784B2 (en) Niacinamide (NAM) in ischemic tissue injury
EP1804824B1 (en) Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
Yamamoto et al. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure
JP6239635B2 (ja) 血管石灰化の誘導因子であるソルチリン１
US20180311356A1 (en) Method to inhibit endothelial-to-mesenchymal transition
Kucherenko et al. Elastin stabilization prevents impaired biomechanics in human pulmonary arteries and pulmonary hypertension in rats with left heart disease
CZ20004358A3 (cs) Farmaceutický prostředek
Cohen et al. Cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody
DE60038740T2 (de) Stimulierung oder hemmung von angiogenese und herzvaskularisierung
Lagoutte et al. Procollagen C-Proteinase Enhancer 1 (PCPE-1) is a marker of myocardial fibrosis and impaired cardiac function in a murine model of pressure overload
US8236488B2 (en) Method of screening for therapeutic compounds for vascular disorders and hypertension based on URAT1 activity modulation
US20090304765A1 (en) R-ras activity in vascular regulation
El Kenani Mechanisms underlying low flow-low gradient aortic stenosis
Philp The potential therapeutic effect of manipulating the extracellular matrix in idiopathic pulmonary fibrosis
Rose The role of GPNMB in breast tumor progression
JP2004113066A (ja) 有機陰イオントランスポーターＯａｔｐ１４又はＯＡＴＰ−Ｆの発現細胞及びその利用方法
IL139687A (en) Use of ß11α integrin receptor inhibitors and TGF β1 inhibitors for the preparation of medicinal preparations for the treatment of kidney disease